For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Universal Health Services, Inc. (UHS) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Gem · Gem Score +41 (−100…+100 Quality+Value blend) · Quality 46 · Value 37 · Sentiment -3 (timing only, not weighted) · Composite fair value $213.57 vs $172.88 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Universal Health Services, Inc.
UHS NYSEUniversal Health Services, Inc. is a healthcare services company that owns and operates a broad network of facilities across the United States. The company focuses on two primary segments: Acute Care Hospital Services and Behavioral Health Services. Its acute care operations include general hospitals, surgical hospitals, freestanding emergency departments, and ambulatory surgery and oncology centers, providing medical, surgical, and emergency care to a wide range of patients. The behavioral health segment delivers inpatient and outpatient services for mental health conditions, substance use disorders, and other behavioral health needs, serving children, adolescents, adults, and seniors. Through these segments, Universal Health Services plays a significant role in the medical care facilities industry, supporting both community-based and specialized care. Headquartered in King of Prussia, Pennsylvania, the company is positioned as a major integrated provider in the U.S. healthcare system, offering essential services that span acute medical treatment, complex behavioral healthcare, and related outpatient services.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 23.10
Total Equity: $7.41B
Shares: 64,462,000
Total Debt: $4.75B
Cash: $137.80M
EBITDA: $2.61B
Total Debt: $4.75B
Cash: $137.80M
Revenue: $17.36B
Revenue: $17.36B
Revenue: $17.36B
Total Equity: $7.41B
Tax Rate: 23.4%
Equity: $7.41B
Total Debt: $4.75B
Cash: $137.80M
Current Liabilities: $3.24B
Long-Term Debt: $4.00B
Total Debt: $4.75B
Total Equity: $7.41B
Shares: 64,462,000
Shares: 64,462,000
CapEx: -$1.02B
Shares: 64,462,000
Stock Price: $170.18
Net Income: $1.49B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 12, 2026 1:16pm (11d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $12.6B | $13.4B | $14.3B | $15.8B | $17.4B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $11.3B | $12.4B | $13.1B | $14.1B | $15.4B |
| Operating Income | $1.4B | $1.0B | $1.2B | $1.7B | $2.0B |
| Net Income | $991.6M | $675.6M | $717.8M | $1.1B | $1.5B |
| EBITDA | $1.9B | $1.6B | $1.7B | $2.3B | $2.6B |
| EPS | $11.99 | $9.23 | $10.35 | $17.16 | $23.42 |
| EPS (Diluted) | $11.82 | $9.14 | $10.23 | $16.82 | $23.10 |
Balance Sheet (Annual)
Last updated: Aug 3, 2026 12:44pm (20d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $115.3M | $102.8M | $119.4M | $126.0M | $137.8M |
| Total Current Assets | $2.3B | $2.5B | $2.8B | $2.8B | $3.4B |
| Total Assets | $13.1B | $13.5B | $14.0B | $14.5B | $15.5B |
| Current Liabilities | $2.0B | $1.9B | $2.0B | $2.2B | $3.2B |
| Long-Term Debt | $4.1B | $4.7B | $4.8B | $4.5B | $4.0B |
| Total Liabilities | $6.9B | $7.5B | $7.8B | $7.7B | $8.1B |
| Total Equity | $6.2B | $6.0B | $6.2B | $6.8B | $7.4B |
| Retained Earnings | $6.6B | $6.5B | $6.8B | $7.4B | $8.0B |
Cash Flow (Annual)
Last updated: Aug 12, 2026 1:16pm (11d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $883.7M | $996.0M | $1.3B | $2.1B | $1.9B |
| Capital Expenditure | -$855.7M | -$734.0M | -$743.1M | -$943.8M | -$1.0B |
| Free Cash Flow | $28.0M | $262.0M | $524.7M | $1.1B | $849.2M |
| Acquisitions (net) | -$105.4M | -$20.3M | -$3.7M | -$19.0M | -$47.8M |
| Net Debt Issued / (Repaid) | -$3.0B | -$89.4M | -$85.5M | -$2.6B | -$43.5M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1.2B | -$832.9M | -$547.4M | -$670.8M | -$968.0M |
| Net Change in Cash | -$1.1B | $21.9M | $13.6M | $10.3M | $46.6M |
Growth Trends (YoY %)
Last updated: Aug 12, 2026 1:16pm (11d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +6.0% | +6.6% | +10.8% | +9.7% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -26.4% | +17.1% | +43.1% | +18.6% |
| Net Income Growth | -31.9% | +6.2% | +59.1% | +30.4% |
| EBITDA Growth | -16.4% | +10.0% | +30.0% | +15.3% |
Dividend History (Last 20)
Last updated: Aug 12, 2026 12:57pm (11d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-08 | $0.20 | — | — | — |
| 2026-03-02 | $0.20 | — | — | — |
| 2025-12-01 | $0.20 | — | — | — |
| 2025-09-02 | $0.20 | — | — | — |
| 2025-06-02 | $0.20 | — | — | — |
| 2025-03-03 | $0.20 | — | — | — |
| 2024-12-03 | $0.20 | — | — | — |
| 2024-09-03 | $0.20 | — | — | — |
| 2024-06-03 | $0.20 | — | — | — |
| 2024-02-29 | $0.20 | — | — | — |
| 2023-11-30 | $0.20 | — | — | — |
| 2023-08-31 | $0.20 | — | — | — |
| 2023-05-31 | $0.20 | — | — | — |
| 2023-02-28 | $0.20 | — | — | — |
| 2022-11-30 | $0.20 | — | — | — |
| 2022-08-31 | $0.20 | — | — | — |
| 2022-05-31 | $0.20 | — | — | — |
| 2022-02-28 | $0.20 | — | — | — |
| 2021-11-30 | $0.20 | — | — | — |
| 2021-08-31 | $0.20 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-20 11:17| Case | Growth | Margin | Fair value | vs price ($172.88) |
|---|---|---|---|---|
| Bull — recovery | +17% | 9.7% | $389.68 | +125% |
| Base — stabilizes | +11% | 8.4% | $289.64 | +68% |
| Bear — keeps slipping | +6% | 7.2% | $210.95 | +22% |
| Stress — last quarter repeats | +8% | 8.0% | $252.59 | +46% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-13Reimbursement is set by government schedules and multi-year payer contracts, not by competitive price discovery, so AI-driven cuts in coding, documentation, prior-auth handling, scheduling and back-office labor across ~400 facilities drop straight into operating margin rather than being competed away.
Payers are deploying AI in utilization review and automated denial at scale; the highest-value target is exactly UHS's behavioral inpatient length-of-stay and acute case-mix intensity, so the provider's own AI gains can be transferred to insurers through denials, downgrades and slower cash conversion.
Whether the AI claims arms race nets in providers' or payers' favor — observable in denial and appeal-overturn rates, days in A/R, bad debt provision, and behavioral segment average length of stay versus admissions growth.
Licensed and certificate-of-need-constrained bed capacity (especially psychiatric, which almost nobody can newly permit), accreditation, in-network payer contracts, and a recruited base of psychiatrists and nurses in supply-short markets.
AI Lens thesis
UHS is a physical-asset, licensed-capacity business whose economics are decided by volume, acuity, reimbursement rates and labor cost — none of which cheap intelligence directly creates or destroys. AI reaches it through three channels: (1) internal cost — revenue cycle, coding, ambient documentation, staffing optimization and centralized shared services, where a 100k+ employee base and 11.5% operating margin mean even 1pp of labor/admin savings is a large earnings delta and, because prices are administratively set, that saving is retained rather than passed through; (2) the payer interface, where insurer AI raises denial density and attacks behavioral LOS and case-mix, potentially confiscating those same gains; (3) demand routing, where AI triage, digital mental-health tools and hospital-at-home monitoring could shave low-acuity outpatient volume while doing nothing to the acute psych and surgical cases that carry margin. Entrant threat is near zero — no amount of cheap software produces a licensed psychiatric hospital.
What the market may be underestimating
Upside Behavioral health is the least digitized, most documentation-heavy, most staffing-constrained care setting in the pool — ambient documentation plus AI scheduling can lift effective clinician capacity in a market where UHS is supply-constrained, converting a labor bottleneck into incremental census at high incremental margin.
Downside AI-assisted audit and coding-pattern analytics (RAC, payer, DOJ) can retrospectively attack case-mix intensity and behavioral admission criteria across a large facility base, turning documentation transparency into recoupment and reputational exposure rather than efficiency.
Outcome range spread 37
Growth Outlook
Analyzed 2026-08-20 11:07The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw print first: UHS is doing ~$18B run-rate revenue (Q2'26 annualized ~$18.6B) versus $15.83B in 2024 — that's real, not accounting. Net income has stepped from ~$258M in Q3'24 to $348-445M range across the last four quarters, with margins holding 7.7-9.9%. Full-year 2025 NI of $1.49B versus $717M in 2023 is a genuine doubling in two years. FCF of $849M on a $10.2B market cap is an 8.3% FCF yield; EV/EBITDA at 5.7x and P/E at 7.5x are hospital-operator trough multiples. Debt/equity 0.64 and $4.75B debt against $1.86B OCF is manageable — leverage isn't the story. This is objectively cheap on printed numbers.
But I want to push back on the synthesis' $286 fair value — that's fantasy math. Hospital operators have traded at 8-12x earnings for a decade for structural reasons: reimbursement is politically administered, labor is unionizing, and behavioral health specifically is under HHS/OIG scrutiny (Acadia's 2024 NYT exposé triggered sector-wide investigations into involuntary holds and length-of-stay practices — UHS's behavioral segment is not immune). A signal-adjusted $286 implies a 12x multiple UHS hasn't sustained since 2015. A more defensible fair value is 9-10x $11 forward EPS = $99-110... wait, TTM EPS is closer to $22-24 given the $1.5B NI on ~65M shares, so 9-10x gets you $200-240. So the direction is right, the magnitude is oversold.
The contrarian case has teeth the market-forces model waves away. First, quarterly margins peaked at 9.9% in Q4'25 and have compressed to 7.7-7.8% in the two 2026 quarters — that's the "decelerating" the revenue confidence flag noted, and it matters because the entire bull case rests on margin durability. Second, Q4'25's $445M NI looks like a one-time tax/reserve benefit given the run-rate reversion — strip it out and 2025 NI is closer to $1.35B, not $1.49B, which pulls the P/E to 8x rather than 7.5x. Third, the 40% drawdown from 52-week highs happened for a reason: consensus likely sees 2026 EPS flat-to-down as Medicaid supplemental payment programs (state directed payments) face CMS review, and UHS disclosed material SDP exposure. The DCF model almost certainly doesn't haircut this. Fourth, current ratio of 1.05 with only $138M cash on $4.75B debt means any working capital hiccup forces the revolver — not fatal, but not the fortress the synthesis implies.
Where I land: the synthesis is directionally correct that UHS is undervalued, but the "+66%" upside is model overreach that ignores why hospital operators structurally trade cheap. The narrative model's "fallen-angel, anchored, minimal intensity" read is the most honest of the prior outputs — this is a boring value setup, not a compounder waiting to be discovered. At 7.5x earnings, 5.7x EBITDA, 8% FCF yield, and 20% ROE, you're being paid to accept reimbursement and margin-mean-reversion risk. The Q1-Q2 2026 margin compression is the tell — if Q3'26 prints below 7.5% margin, the bear case is validated and fair value is $150-165. If margins stabilize at 8%+, $210-230 is reasonable. I dissent on magnitude but agree on direction: this is undervalued, but call it $200 fair value, not $286, and size accordingly given the behavioral-health regulatory tail risk that no model here has properly weighted.
GPT Reading
What stands out is how much of UHS’s improvement is already hard evidence rather than aspiration. Revenue has risen from $12.64B in 2021 to $17.36B in 2025, a 37% increase, while net income went from $991.6M to $1.49B despite the ugly dip in 2022-23. More importantly, the business has clearly re-established margin power: operating income climbed from $1.68B in 2024 to $1.99B in 2025, lifting operating margin from 10.6% to 11.5%, and quarterly net margins have stabilized mostly in the 7.7%-9.9% range over the last six quarters versus 6.5% in 2024’s September quarter. The first half of 2026 continues that trend in dollars if not margins: revenue of $9.14B is up 9.8% from $8.38B in 1H25, and net income of $707.1M is up 5.8% from $669.9M. That is not a distressed operator or a melting-ice-cube hospital chain. It is a scale healthcare asset producing nearly $1.9B of operating cash flow and $849M of free cash flow after a heavy $1.02B capex program.
At $10.2B market cap and $177.61 per share, the valuation is simply low relative to those facts. A 7.5x P/E, 5.7x EV/EBITDA, 0.86x EV/revenue, and 1.5x book for a business generating 20% ROE and 12.7% ROIC is the kind of multiple usually reserved for earnings that the market thinks are about to roll over. But the reported numbers do not show rollover. Even if I haircut 2025 net income of $1.49B and assume a more normalized run-rate around $1.35B-$1.40B because 1H26 margins are a touch softer than the 2025 exit, the stock is still around 7.3x-7.6x that earnings base. For a company with mid-to-high single-digit top-line growth and decent balance-sheet tolerance—$4.75B debt against $7.41B equity, debt/equity 0.64—that is too cheap. The market seems to be valuing UHS as though reimbursement and labor will fully negate volume growth; instead, the data say UHS has been passing through enough pricing and operating leverage to grow earnings materially faster than revenue over the cycle.
I also think some of the “mature earner” framing risks understating the quality of the setup. This is not a no-growth utility earning a fair 10x. Revenue has compounded at over 10% from the provided period, and earnings have rebounded sharply from the 2023 trough of $717.8M to $1.49B in 2025. The share price does not appear to be crediting that rebound as durable. Yet UHS is not funding growth with balance-sheet strain or accounting smoke: operating cash flow of $1.86B comfortably supports capex, and while cash on hand is thin at $137.8M, that is not unusual for a stable operator with recurring collections and asset backing. If anything, the low cash balance is one of the few superficially scary figures that looks less important in context than the earnings and cash generation power.
The best case against this bullish read is that 2025 may have been closer to a local peak than a new base. Quarterly revenue has flattened around $4.49B-$4.64B for four straight quarters, and net margin has slipped from 9.9% in 2025’s December quarter to 7.8%-7.7% in the first two quarters of 2026. If that is the beginning of renewed labor inflation, reimbursement pressure, or a tougher payer mix, then annualizing 1H26 gets you roughly $1.41B of net income—still good, but not really growing versus 2025. In that scenario, the low multiple is not a mistake but recognition that hospital earnings are cyclical, regulated, and vulnerable to small cost swings. Bears can also point to the 2021-2023 path: revenue kept rising, but net income fell from $991.6M to $675.6M and then $717.8M, proving this business is not structurally immune to margin compression. I weigh that differently because today’s valuation already embeds a lot of that skepticism; if 2026 is merely flat-to-slightly-up earnings rather than a collapse, the current multiple is too pessimistic.
What would change my mind is not a macro headline but evidence that 2026 margins are normalizing materially below 2025. If the next two quarters show revenue growth slowing to low single digits while net margin falls toward 6%-7%, taking annualized earnings below about $1.25B, then the “cheap compounder” case breaks and the stock deserves to stay trapped in a single-digit multiple. Likewise, a meaningful deterioration in operating cash flow relative to earnings, or debt stepping up without a corresponding return, would tell me 2025 cash conversion overstated real economics. Short of that, I think the stock is mispriced: UHS looks like a solid, cash-generative operator being valued as if its recovery has already begun to reverse.
Grok Reading
The raw numbers describe a facilities operator that has quietly compounded its way out of a trough. Revenue climbed from $12.64B in 2021 to $17.36B in 2025 at a 10.3% CAGR, with the latest two quarters still printing $4.50B and $4.64B — roughly 9–10% year-over-year. More striking is the earnings path: net income went from $718M in 2023 to $1.14B in 2024 to $1.49B in 2025, a 44% earnings CAGR that lifted operating margin to 11.5% and ROE to 20.1%. Free cash flow of $849M against a $10.2B market cap is an 8.3% FCF yield, and EV/EBITDA of 5.7x with a 7.5x P/E puts the stock below any reasonable no-growth floor for a dual-segment acute-plus-behavioral hospital chain that is still growing mid-to-high single digits. The balance sheet is levered but not reckless — $4.75B debt against $7.41B equity (D/E 0.64) and ROIC of 12.7% — so the capital structure can support the $1.02B capex program without distress. At $177.61 the market is simply not paying for the improvement already delivered.
What stands out as a tension inside the data is the shape of the margin recovery. The December 2025 quarter spiked to a 9.9% net margin on $446M of net income; the two subsequent quarters snapped back to 7.8% and 7.7%. That reversion matters. Annual 2025 net margin of 8.6% embeds a peak that has already partially faded, so trailing earnings overstate the current run-rate by roughly $100–150M. Even so, annualizing the last two quarters still produces something like $1.4B of net income — a mid-7x multiple on normalized earnings — and revenue has not stalled. The behavioral health franchise, which the pre-flight correctly flags as structurally undersupplied, is the most plausible source of the operating leverage that remains; acute care alone does not produce 30% earnings growth on 10% revenue growth. Cash is uncomfortably thin at $138M against that debt load, and the current ratio of 1.05 leaves little working-capital cushion, but operating cash flow of $1.86B dwarfs near-term maturities in a normal rate environment.
The valuation synthesis’s $214–$287 fair-value band is directionally right but too aggressive on the upper end. A 10–11x earnings multiple on a $1.4–1.5B normalized net income base, or 7–8x EV/EBITDA, lands closer to $210–$240; the $286 figure requires both sustained high-single-digit growth and a re-rating that the sector has not granted hospital operators for years. Still, even the conservative end of that range is 18–35% above the current print. The “fallen angel / minimal narrative” framing is accurate: there is no cult premium, no TAM story, and institutional holders are treating this as a skeptical value name rather than a compounder. That discount is the opportunity if execution holds.
The strongest opposing case is that the market has already diagnosed the right risks and is correctly refusing to pay up. CMS reimbursement pressure, labor inflation that has historically outrun rate increases, and heightened regulatory scrutiny of behavioral length-of-stay and intake practices are not theoretical — they are the reason the entire medical-care-facilities cohort trades at a discount to the broader market. Sector intelligence already flags UHS as below benchmarks. The Q4 2025 margin spike followed by two quarters of mean-reversion looks exactly like the kind of non-recurring mix or one-time item that value traps produce before earnings stall. Debt of $4.75B with negligible cash means any sustained compression in EBITDA or a refinancing window at higher spreads immediately pressures FCF and equity value. If the bear story is right — that 2024–25 was a cyclical peak in volumes and payer mix rather than a new structural margin plateau — then 7.5x trailing earnings is not cheap; it is a fair multiple on a business about to decelerate into mid-single-digit earnings growth or worse. I weigh this less heavily than the bulls’ absence would suggest because trailing FCF is still robust, revenue has not rolled over, and a 20% ROE business at 1.5x book rarely stays this inexpensive without an actual earnings break.
What would flip the view: two more quarters of net margins stuck at or below 7.5% with revenue growth slipping under 5% would confirm the peak-earnings thesis and push the stock toward fairly valued or worse near $160–170. Conversely, a clean print showing net margins re-expanding toward 8.5%+ alongside continued double-digit behavioral volume growth, or a material debt paydown that lifts the current ratio and cuts net leverage, would justify moving conviction higher and chasing a re-rating toward $230+. A clear adverse CMS behavioral-health rule or a spike in bad-debt expense would be immediate thesis breakers on the downside.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Universal Health Services shows a clean operating trajectory: revenue grew from $12.64B (2021) to $17.36B (2025), a ~8% CAGR, while operating margin expanded from a 2022 trough of 7.5% back to 11.5% in 2025 and net income rose from $675.6M to $1.49B. Cash conversion is genuine — OCF/NI at 1.44x, accruals at -2.9% of assets, and FCF of $849M in 2025 (down from an unusually strong $1.12B in 2024 but well above the 2021-2023 range). Altman Z of 3.03 sits in the safe zone and earnings-quality mechanical checks flag nothing.
Verify before trusting this (5)
- Debt maturity schedule and refinancing terms for the $748M short-term portion
- Payor mix and Medicaid supplemental payment exposure driving the 2024-2025 margin lift
- Sustainability of behavioral-segment volume and pricing trends
- Any contingent liabilities from ongoing government investigations or malpractice
- Capex intensity vs. maintenance needs given FCF variability
The composite fair value of $213.57 implies ~24% upside from $172.88, and the EPV floor at $189.08 - which values only current earning power with no growth heroics - already sits ~9% above the price. That EPV floor is the important number: even in a no-growth world, the business appears worth more than the tape. The signal-adjusted $286.56 (66% upside) looks like a runaway output and I discount it heavily; I would not underwrite anything above the $213-225 DCF range. Earnings quality is high (score 3), so no haircut needed, and the Strong quality grade supports carrying the deserved value near the DCF rather than the EPV. What is priced in at $172.88 is essentially stagnation plus continued labor-cost worry and CMS/behavioral-health regulatory overhang. What is NOT required to justify today's price is any meaningful margin expansion, acquisition-driven growth, or benefit from buyback-driven per-share compounding - all of which are actually happening. That asymmetry is the mispricing. It is not a fat pitch: leverage is real, cash is thin, and behavioral-health regulatory risk is a genuine tail. But the gap between $173 and a deserved ~$210 on a cash-generative operator shrinking its share count ~5%/yr is a legitimate, if modest, discount.
Verify before trusting this (5)
- Behavioral health same-facility revenue and adjusted admissions trends in the latest 10-Q
- CMS rate updates and any Medicaid supplemental payment program changes affecting FY guidance
- Labor cost per adjusted admission - is the 2022 trough recovery still intact
- Net debt / EBITDA trajectory and remaining buyback authorization
- Any DOJ/OIG behavioral-health inquiry disclosures in recent filings
The macro backdrop is mildly risk-on with a subdued VIX and a neutral rate/curve setup, which for a beta-1.06 hospital operator is close to a wash - defensives don't lead in risk-on tapes, but nothing in the regime is actively punishing UHS either. The prevailing narrative is a low-intensity fallen-angel: the market is discounting reimbursement pressure, labor costs, and behavioral-health regulatory scrutiny, and that story is durable but not urgent, so it presses steadily rather than violently on the price. There is no cult, no mania, no collapsing thesis - just a name the market has decided not to get excited about. The most recent news skews modestly constructive: the completed Talkspace acquisition gives UHS a fresh, ownable virtual behavioral-health angle that headline writers can latch onto, and Q2 hospital-chain wrap-ups placed UHS in the group without singling it out negatively. Analyst tone reads muted rather than hostile. Net: a low-amplitude story, a benign tape, and a small self-generated tailwind from Talkspace roughly offset the fallen-angel drag - pressure is genuinely balanced with a whisper of upside.
Verify before trusting this (4)
- Whether sell-side revisions post-Talkspace close skew positive or treat it as dilutive
- Any CMS reimbursement headline or behavioral-health regulatory action that would reawaken the fallen-angel narrative
- Rotation signals within hospital chains - if THC keeps outperforming, UHS stays the group laggard
- Whether Talkspace integration commentary at the next print builds or breaks the virtual-care storyline
UHS is a physical-asset, licensed-capacity business whose economics are decided by volume, acuity, reimbursement rates and labor cost — none of which cheap intelligence directly creates or destroys. AI reaches it through three channels: (1) internal cost — revenue cycle, coding, ambient documentation, staffing optimization and centralized shared services, where a 100k+ employee base and 11.5% operating margin mean even 1pp of labor/admin savings is a large earnings delta and, because prices are administratively set, that saving is retained rather than passed through; (2) the payer interface, where insurer AI raises denial density and attacks behavioral LOS and case-mix, potentially confiscating those same gains; (3) demand routing, where AI triage, digital mental-health tools and hospital-at-home monitoring could shave low-acuity outpatient volume while doing nothing to the acute psych and surgical cases that carry margin. Entrant threat is near zero — no amount of cheap software produces a licensed psychiatric hospital.
None surfaced.
Verify before trusting this (8)
- SG&A and admin cost per admission
- Salaries/wages as % of revenue
- CMS market-basket productivity cuts
- Contract labor as % of salaries
- Nurse/psychiatrist vacancy rates
- New behavioral bed additions
- Behavioral average length of stay
- Revenue per adjusted patient day
Utilization in US hospital and behavioral networks remains structurally elevated: an aging population, post-pandemic acuity, and a behavioral bed shortage that capital cannot fix quickly because licensure and clinical staffing — not buildings — are the binding constraint. That favors incumbent scaled operators like UHS over the next two years. The countervailing force is entirely policy, not demand: the coverage architecture that converted this utilization into paid revenue is being narrowed at both ends — exchange subsidies lapsing and state directed-payment arbitrage being legislated down toward Medicare rates. So the world read splits cleanly: volume and acuity tailwinds are durable; the reimbursement per unit of that volume is the variable being taken away later in the window. Macro itself is close to neutral for the business — a 4.71% 10-year matters mainly to the cost of the capex/buyback program, not to patient demand, which is essentially non-cyclical.
When we made this prediction on Aug 20, 2026, UHS was $173.28. We expect it to be $197.50 by Feb 2027, and we consider it great value under $165.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 20, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.